Thinking Outside the Box: Indirect Myc Modulation in Canine B-Cell Lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Veterinary Medicine

Background:

• Canine B-cell lymphoma (BCL) is a common hematological cancer in dogs.
• Current treatments like CHOP chemotherapy offer limited success, necessitating novel therapeutic strategies.
• Dysregulation of the Myc transcription factor is implicated in canine BCL (cBCL) pathogenesis.

Purpose of the Study:

• To evaluate the efficacy of indirectly inhibiting Myc in canine BCL models.
• To assess the effects of BI2536 and MZ1 compounds on cBCL cell lines.
• To explore novel therapeutic approaches targeting Myc in canine hematological malignancies.

Main Methods:

• Utilized two canine B-cell lymphoma in vitro models (CLBL-1 and KLR-1201).
• Administered BI2536 and MZ1 compounds, both individually and in combination.
• Assessed cell viability, protein expression (Western Blot), and transcriptomic changes.

Main Results:

• BI2536 and MZ1 significantly reduced cell viability in a dose- and time-dependent manner.
• BI2536 upregulated PLK1 and reduced c-Myc; MZ1 decreased BRD4 and c-Myc.
• BI2536 induced broader transcriptomic changes affecting MYC targets and cell cycle genes compared to MZ1.

Conclusions:

• Myc represents a potential therapeutic target for canine B-cell lymphoma.
• Indirect Myc inhibition using BI2536 and MZ1 shows promise for cBCL treatment.
• These findings offer a novel strategy for modulating Myc in canine hematological cancers.